Ipamorelin vs GHRP-2: Evidence and FDA Status
Compare ipamorelin and GHRP-2 by receptor action, hormone selectivity, appetite effects, human evidence, safety, FDA status, and anti-doping rules.
Ipamorelin and growth hormone-releasing peptide 2 (GHRP-2, also called pralmorelin) are synthetic peptides that activate the ghrelin receptor and can trigger growth hormone release. They share a receptor class, but they are not interchangeable and neither has an FDA-approved therapeutic use in the United States.
The clearest supported difference is hormonal selectivity. Ipamorelin produced a more GH-selective response than GHRP-2 in the original animal comparison. Small human studies of GHRP-2 found increases in growth hormone alongside ACTH, cortisol, prolactin, or appetite. No direct human head-to-head trial identified in this review establishes that one is safer or clinically better.
Comparison at a glance
Status is current through August 29, 2026 and refers to the United States unless noted.
| Question | Ipamorelin | GHRP-2 |
|---|---|---|
| Peptide structure | Synthetic pentapeptide | Synthetic hexapeptide |
| Primary receptor | Growth hormone secretagogue receptor 1a, or GHS-R1a | GHS-R1a |
| Established acute effect | Growth hormone release in animal studies and healthy male volunteers | Growth hormone release in small human challenge studies |
| Hormone selectivity | More selective for GH than GHRP-2 in the original conscious-swine comparison; equivalent human selectivity is not established | Human studies report additional ACTH, cortisol, and prolactin responses |
| Appetite evidence | Insufficient controlled human evidence for a comparison | Increased food intake in small randomized human studies |
| Therapeutic outcome evidence | A phase 2 postoperative-ileus trial did not meet its key efficacy endpoint | Evidence is dominated by acute endocrine and diagnostic-response studies rather than therapeutic outcome trials |
| FDA approval | Not FDA-approved | Not FDA-approved |
| Compounded-product review | FDA has raised characterization, immunogenicity, and safety concerns | FDA lists injectable and nasal compounded GHRP-2 among substances that may present significant safety risks |
| WADA status | Prohibited at all times under the 2026 list | Prohibited at all times under the 2026 list |
How both peptides affect the GH axis
Both peptides activate GHS-R1a, the receptor associated with ghrelin signaling. This is a different entry point from a GHRH analog such as sermorelin or tesamorelin:
- a ghrelin-receptor agonist activates GHS-R1a in the pituitary and hypothalamic system;
- a GHRH analog activates the GHRH receptor on pituitary somatotroph cells; and
- somatropin supplies recombinant growth hormone directly.
GHS-R1a activation can produce a pulse of growth hormone, which may then influence downstream IGF-1 signaling. It can also affect systems outside the growth hormone axis because ghrelin receptors participate in appetite, energy balance, gastrointestinal motility, and neuroendocrine signaling.
That mechanism does not prove muscle gain, fat loss, injury recovery, better sleep, or longer life. Acute changes in growth hormone are biomarker findings, not substitutes for controlled clinical outcomes.
What “more selective” actually means
The 1998 paper that introduced ipamorelin compared several secretagogues in rat pituitary cells, anesthetized rats, and conscious swine. In swine, GHRP-2 was more potent but had a lower maximum growth-hormone response than ipamorelin. GHRP-2 and GHRP-6 also increased ACTH and cortisol, while ipamorelin did not increase those hormones beyond the response observed with GHRH (Raun et al., 1998).
This supports a precise statement: ipamorelin was more selective for GH release in those preclinical models. It does not establish that ipamorelin has fewer adverse effects, produces better body composition, or is safer during repeated use in people.
Human GHRP-2 challenge studies help explain the comparison. In six young adults, intravenous GHRP-2 caused a strong growth-hormone response and also increased prolactin, ACTH, and cortisol (Arvat et al., 1997). The study was small and examined short-term hormone responses, not long-term safety or treatment benefit.
Human evidence for ipamorelin
Healthy-volunteer pharmacology
A dose-escalation study assigned eight healthy men to each of five intravenous infusion levels. Ipamorelin caused one episode of growth-hormone release, peaking at about 0.67 hours, with substantial variability between individuals. The estimated terminal half-life was about two hours (Gobburu et al., 1999).
This study confirms acute pharmacology. It did not test muscle growth, fat loss, sleep, recovery, aging, or long-term subcutaneous use.
Postoperative ileus trial
Ipamorelin was later studied as an intravenous treatment for postoperative ileus after bowel resection. The phase 2 randomized, double-blind trial enrolled 117 patients; 114 were included in the safety and modified intention-to-treat populations. Median time to a first tolerated solid meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, but the difference was not statistically significant (p = 0.15) (Beck et al., 2014).
FDA's 2024 compounding review noted higher numerical rates of hypokalemia and hyperglycemia in ipamorelin-treated participants. Two ipamorelin-treated participants died after serious postoperative complications; FDA and the study authors did not establish that ipamorelin caused those deaths. The agency also noted that the trial used intravenous administration and did not provide safety evidence for the subcutaneous route proposed by compounders (FDA briefing document).
The balanced conclusion is that ipamorelin reached human clinical development but did not demonstrate efficacy for postoperative ileus in this trial. That history does not validate unrelated wellness or performance uses.
Human evidence for GHRP-2
GHRP-2 has been used mainly as an experimental endocrine stimulus. Small studies show that it can acutely release growth hormone, including in healthy adults and selected clinical populations. Those studies help characterize the axis but are not evidence that repeated GHRP-2 improves health outcomes.
Hormone responses extend beyond GH
The six-person young-adult study above found ACTH, cortisol, and prolactin responses in addition to growth hormone. Other challenge studies have used GHRP-2 to examine pituitary and adrenal responsiveness. That broader hormonal activity is why describing GHRP-2 as simply a stronger version of ipamorelin is misleading.
Appetite increased in controlled studies
In a randomized crossover study of seven healthy men, participants consumed about 36% more during an unrestricted meal after a GHRP-2 infusion than after saline (Laferrère et al., 2005). A later randomized study of 19 lean and obese adults found a dose-dependent increase in food intake, with no meaningful difference in the response by obesity status (Laferrère et al., 2006).
These acute feeding studies do not establish long-term weight gain or loss. They do directly contradict the old page's claim that ghrelin analogs steer people toward foods that promote lean mass or support obesity treatment.
Claims the comparison does not support
Muscle gain and fat loss
Growth hormone and IGF-1 participate in body-composition physiology, but neither peptide has controlled human evidence here demonstrating meaningful muscle gain or fat loss. Yak, pig, rat, or cell findings cannot establish a bodybuilding or weight-management treatment in humans.
Bone density
Ipamorelin has preclinical bone studies, including glucocorticoid-treated rats. Those experiments can support further research but do not prove fracture prevention, improved bone density, or treatment of osteoporosis in people.
Sleep and cognition
The old comparison claimed that GHRP-2 improved deep and REM sleep by citing a study of MK-677, a different oral growth hormone secretagogue. That study cannot be assigned to GHRP-2. No comparative sleep or cognitive benefit between ipamorelin and GHRP-2 was established in the evidence reviewed.
Pain relief
GHRP-2 antinociception has been reported in mice. A mouse opioid-receptor experiment does not establish an analgesic effect, safe dose, or reduced addiction risk in humans.
Anti-aging or longevity
Age-related changes in growth hormone and IGF-1 do not show that raising either marker slows aging. Neither peptide has demonstrated longer life, longer healthspan, or an FDA-approved anti-aging use. The IGF-1 evidence guide explains why both low and high values can be associated with risk.
FDA and compounding status
Neither ipamorelin nor GHRP-2 is a component of an FDA-approved human drug in the United States. A compounded preparation is not FDA-approved, and FDA does not review compounded drugs before marketing for safety, effectiveness, or quality (FDA compounding questions and answers).
Current FDA materials add substance-specific context:
- FDA's ipamorelin evaluation found insufficient effectiveness and safety evidence for the proposed compounded uses and raised concerns about peptide characterization, aggregation, impurities, and immunogenicity. The agency proposed against adding ipamorelin free base or acetate to the 503A Bulks List.
- The current FDA compounding safety page lists ipamorelin acetate under the 503B interim policy and says the agency lacks enough information to know whether certain injectable routes would cause harm.
- The May 2026 503A categories document places GHRP-2 in Category 3, meaning it was nominated without adequate support. FDA separately lists injectable and nasal GHRP-2 among bulk substances that may present significant safety risks because of aggregation, impurities, characterization, and reported adverse events for which causality was not established.
A compounding category is not an approval, a finding of clinical effectiveness, or validation of a particular finished product.
Anti-doping status
The 2026 World Anti-Doping Agency Prohibited List names ipamorelin among growth hormone secretagogues and GHRP-2 among growth hormone-releasing peptides. Both are prohibited at all times for athletes subject to WADA rules.
“Research use only,” a prescription, or a compounded label does not automatically create a sports exemption. Athletes should use their anti-doping organization's formal medication and therapeutic-use-exemption resources.
Which peptide is better?
The evidence does not support an overall ranking.
- For receptor pharmacology: both activate GHS-R1a.
- For GH selectivity: ipamorelin looked more selective in the original animal comparison, but that is not a human safety verdict.
- For appetite: GHRP-2 has direct human evidence of increasing short-term food intake.
- For therapeutic benefit: neither has an FDA-approved indication, and the cited research does not establish bodybuilding, fat-loss, recovery, sleep, or anti-aging benefits.
- For product safety: neither has the product-specific FDA review and labeling that an approved drug receives.
The meaningful research choice depends on the exact hypothesis and evidence layer, not a general claim that one peptide is “cleaner,” “stronger,” or safer.
Research questions to ask
- Is the claim about a hormone pulse or a patient outcome? These are not equivalent endpoints.
- Was the study conducted in humans? Many comparative claims come from rats, pigs, swine, yaks, or mice.
- Was the comparison direct? Separate experiments do not establish relative efficacy or safety.
- Which route and product were studied? Intravenous clinical-trial material does not validate a subcutaneous or nasal compounded product.
- Were ACTH, cortisol, prolactin, glucose, and IGF-1 measured? “GH selective” requires more than a growth-hormone result.
- Is the citation about the same compound? Evidence for MK-677, GHRP-6, hexarelin, ghrelin, or somatropin cannot automatically be assigned to ipamorelin or GHRP-2.
Frequently asked questions
Are ipamorelin and GHRP-2 the same peptide?
No. Ipamorelin is a synthetic pentapeptide and GHRP-2 is a synthetic hexapeptide. Both activate GHS-R1a, but their structures and observed hormone-response profiles differ.
Does ipamorelin raise cortisol or prolactin?
The original animal comparison found substantially greater GH selectivity for ipamorelin than for GHRP-2. That does not prove that repeated ipamorelin use never affects cortisol, prolactin, or other systems in humans.
Does GHRP-2 increase hunger?
Yes, acute controlled human studies found increased appetite and food intake after GHRP-2 infusion. Those short studies do not predict an individual's long-term weight change.
Is ipamorelin safer than GHRP-2?
No direct human evidence establishes a general safety ranking. Ipamorelin's selectivity finding is mainly preclinical, and FDA has raised distinct safety and product-quality concerns for compounded preparations of both substances.
Is either peptide FDA-approved?
No. Neither ipamorelin nor GHRP-2 is an FDA-approved human drug in the United States. Compounded versions are not FDA-approved.
Can either peptide be used by tested athletes?
Both are prohibited at all times under the 2026 WADA list. Athletes should verify current rules and any therapeutic-use-exemption requirements with their governing anti-doping organization.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PMID: 9849822.
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharmaceutical Research. 1999. PMID: 10496658.
- Beck DE, et al. Randomized proof-of-concept study of ipamorelin for postoperative ileus. International Journal of Colorectal Disease. 2014. PMID: 25331030.
- Arvat E, et al. Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH, and cortisol in humans. Peptides. 1997. PMID: 9285939.
- Laferrère B, et al. GHRP-2 increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism. 2005. PMID: 15699539.
- Laferrère B, et al. Obese subjects respond to GHRP-2's stimulatory effect on food intake. Obesity. 2006. PMID: 16861611.
- FDA. Evaluation of ipamorelin-related bulk drug substances for the 503A Bulks List. 2024.
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.
- FDA. Bulk drug substances nominated under section 503A. Updated May 14, 2026.
- World Anti-Doping Agency. 2026 Prohibited List.
Continue researching
- Review the ipamorelin profile
- Review the GHRP-2 profile
- Understand growth hormone secretagogue receptors
- Compare sermorelin and human growth hormone
- Understand the downstream IGF-1 pathway
- Review peptide regulatory status
- Learn how to evaluate peptide studies
- Check disclosed source availability separately
Ipamorelin vs CJC-1295: Evidence, DAC, and Safety
Compare Ipamorelin and CJC-1295 mechanisms, DAC and no-DAC naming, human GH evidence, combination gaps, safety, FDA status, and sourcing checks.
Sermorelin vs HGH: FDA Status and Clinical Evidence
Compare sermorelin with recombinant human growth hormone (somatropin) by mechanism, FDA status, pediatric and adult evidence, safety, and research limits.